[1] |
SUNG H, FERLAY J, SIEGEL R L,et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249. DOI: 10.3322/caac.21660.
|
[2] |
ISIK B, GONULTAS F, SAHIN T,et al. Microvascular venous invasion in hepatocellular carcinoma:why do recurrences occur?[J]. J Gastrointest Cancer, 2020, 51(4):1133-1136. DOI: 10.1007/s12029-020-00487-9.
|
[3] |
|
[4] |
YANG P H, SI A F, YANG J,et al. A wide-margin liver resection improves long-term outcomes for patients with HBV-related hepatocellular carcinoma with microvascular invasion[J]. Surgery, 2019, 165(4):721-730. DOI: 10.1016/j.surg.2018.09.016.
|
[5] |
ZHANG W H, LIU Z K, CHEN J L,et al. A preoperative model for predicting microvascular invasion and assisting in prognostic stratification in liver transplantation for HCC regarding empirical criteria[J]. Transl Oncol, 2021, 14(11):101200. DOI: 10.1016/j.tranon.2021.101200.
|
[6] |
LEI Z Q, LI J, WU D,et al. Nomogram for preoperative estimation of microvascular invasion risk in hepatitis B virus-related hepatocellular carcinoma within the Milan criteria[J]. JAMA Surg, 2016, 151(4):356-363. DOI: 10.1001/jamasurg.2015.4257.
|
[7] |
MIZEJEWSKI G J. Does alpha-fetoprotein contribute to the mortality and morbidity of human hepatocellular carcinoma? A commentary[J]. J Hepatocell Carcinoma, 2016, 3:37-40. DOI: 10.2147/JHC.S114198.
|
[8] |
|
[9] |
NITTA H, ALLARD M A, SEBAGH M,et al. Predictive model for microvascular invasion of hepatocellular carcinoma among candidates for either hepatic resection or liver transplantation[J]. Surgery, 2019, 165(6):1168-1175. DOI: 10.1016/j.surg.2019.01.012.
|
[10] |
WU Y F, TU C Y, SHAO C X. The value of preoperative systemic immune-inflammation index in predicting vascular invasion of hepatocellular carcinoma:a meta-analysis[J]. Rev Bras De Pesquisas Med E Biol, 2021, 54(4):e10273. DOI: 10.1590/1414-431X202010273.
|
[11] |
SZCZERBA B M, CASTRO-GINER F, VETTER M,et al. Neutrophils escort circulating tumour cells to enable cell cycle progression[J]. Nature, 2019, 566(7745):553-557. DOI: 10.1038/s41586-019-0915-y.
|
[12] |
|
[13] |
WANG L, JIN Y X, JI Y Z,et al. Development and validation of a prediction model for microvascular invasion in hepatocellular carcinoma[J]. World J Gastroenterol, 2020, 26(14):1647-1659. DOI: 10.3748/wjg.v26.i14.1647.
|
[14] |
ZHOU K, GAO C F, ZHAO Y P,et al. Simpler score of routine laboratory tests predicts liver fibrosis in patients with chronic hepatitis B[J]. J Gastroenterol Hepatol, 2010, 25(9):1569-1577. DOI: 10.1111/j.1440-1746.2010.06383.x.
|
[15] |
YAVUZ B G, PESTANA R C, ABUGABAL Y I,et al. Origin and role of hepatic myofibroblasts in hepatocellular carcinoma[J]. Oncotarget, 2020, 11(13):1186-1201. DOI: 10.18632/oncotarget.27532.
|
[16] |
O'ROURKE J M, SAGAR V M, SHAH T,et al. Carcinogenesis on the background of liver fibrosis:implications for the management of hepatocellular cancer[J]. World J Gastroenterol, 2018, 24(39):4436-4447. DOI: 10.3748/wjg.v24.i39.4436.
|
[17] |
GIRÓN-GONZÁLEZ J A, MARTÍNEZ-SIERRA C, RODRIGUEZ-RAMOS C,et al. Implication of inflammation-related cytokines in the natural history of liver cirrhosis[J]. Liver Int, 2004, 24(5):437-445. DOI: 10.1111/j.1478-3231.2004.0951.x.
|
[18] |
|
[19] |
ZHANG L X, LV Y, XU A M,et al. The prognostic significance of serum gamma-glutamyltransferase levels and AST/ALT in primary hepatic carcinoma[J]. BMC Cancer, 2019, 19(1):841. DOI: 10.1186/s12885-019-6011-8.
|
[20] |
TEIJEIRA A, GARASA S, GATO M,et al. CXCR1 and CXCR2 chemokine receptor agonists produced by tumors induce neutrophil extracellular traps that interfere with immune cytotoxicity[J]. Immunity, 2020, 52(5):856-871. DOI: 10.1016/j.immuni.2020.03.001.
|
[21] |
|